BEIJING
- China's pharmaceutical industry witnessed good
development momentum in the first half of 2005,
with profits and sales concentrated in large
enterprises.
Jiangsu Province in east
China is leading the pharmaceutical industry with
a profit of 2.947 billion yuan in the first half.
China's Shandong Province
registered 24.665 billion yuan (US$3 billion) in
sales value in the period, ranking first in the
country, surging by 49.81%, 8 percentage points
higher than in the first quarter. Its profit
jumped by 55.37%, 11 percentage points more than
in the first quarter. The sales and profits in
Jiangsu, Shandong and Zhejiang provinces each
accounted for at least 10% of the total in the
country, while the top 15 provinces monopolized
85.01% of the sales and profits.
Large
drug companies contribute more The top 100
enterprises generated a combined sales revenue of
93.63 billion yuan in the first six months, 47.4%
of the industry's
total. The Shanghai
Pharmaceutical (Group) Co Ltd (SPGC) recorded the
biggest sales of 10.38 billion yuan, followed by
Guangzhou Pharmaceutical Holdings Ltd (GPC) with
7.2 billion yuan.
The 28 crude chemical
drug enterprises raked in a combined 26.7 billion
yuan in sales revenue, occupying 28.5% of the top
100s total; 26 chemical drugs and preparations
manufacturers registered 19.22 billion yuan,
20.53% of the total; 29 Chinese patent medicines
producers, 1.9 billion yuan, 23.4% of the total; 4
biomedicine enterprises, 2.96 billion yuan; 7
medical apparatus makers, 3.33 billion yuan; and
the rest including SPGC and GPC acquired a
combined 17.934 billion yuan.
Ten
state-owned enterprises achieved 13.546 billion
yuan in sales revenue; 54 joint stock enterprises
generated 61.3 billion yuan; 29 Hong
Kong, Macau and foreign-funded
enterprises, 15.17 billion yuan; and six other
types of enterprises, 3.24 billion yuan.
Joint stock companies took up 51.72% of
the sales revenue from chemical drugs and
preparations, ranking first in the country, and
Hong Kong, Macau and foreign-funded companies
accounted for 45.67%, ranking 2nd. The sales
revenue of crude chemical drugs mainly came from
joint stock and state-owned companies, accounting
for 48.45% and 45.99%, respectively.
Joint
stock companies in biomedicine clinched 77.91% of
the total sales revenue, foreign-funded companies
occupied 74.71% of the medical apparatus industry,
and joint stock companies accounted for 73.09% of
the Chinese patent medicines industry.
About 57.85% of the Hong Kong, Macau, Taiwan and foreign-funded
companies listed among the top 100 were engaged in
the chemical drugs and preparations business,
7.45% in the crude chemical drugs sector, 16.38%
in the medical apparatus sector and 14.28% in the
Chinese patent medicines sector.
Meanwhile, joint stock companies took up
26.13% of the Chinese patent medicines sector,
21.12% in the crude chemical drugs sector and
16.23% in the chemical drugs and preparations
sector, respectively. Some 90.68% of the
state-owned companies gathered in the crude
medical drugs sector.
Top profit
earners The top 100 profit-earning
enterprises registered 9.33 billion yuan of profit
in the first half of the year, 55% of the
industry's total, with the Yangtze Pharmaceutical
Group ranking first with 469 million yuan profit
in H1.
The chemical drugs and preparations
industry realized a top profit of 3.13 billion
yuan, followed by the Chinese patent medicines
industry and crude chemical drugs sector, with
2.38 billion yuan and 1.879 billion yuan,
respectively. The first three sectors made up
79.26% of the total profit of the top 100 firms.
About 34.48% of the profits in the medical
apparatus sector came from the top 100
enterprises, while the proportion in the
biomedicine sector was 47.7%.
The top 100
enterprises involved 35 chemical drugs and
apparatus producers, 21 of which came from Hong
Kong, Macau, Taiwan and foreign countries; 21
crude chemical drugs producers, including 9 joint
stock companies, 5 Hong Kong, Macau, Taiwan and
foreign-funded companies and 6 state-owned ones;
24 Chinese patent medicines enterprises, including
16 joints stock companies, 4 Hong Kong, Macau,
Taiwan and foreign-funded companies, one
state-owned one, one collectively-owned company,
and two of other types; 9 biomedicine enterprises,
including 5 joint stock companies; and 5 medical
apparatus manufacturers, all from Hong Kong,
Macau, Taiwan and foreign countries.
Among
the top 100 profitable enterprises located in 24
provinces, the profit of those from Jiangsu ranked
first, with 1.586 billion yuan, 17% of the total;
while the proportion was more than 10% in Zhejiang
and Shandong, respectively, and around 8% in Beijing, Guangdong and Shanghai.
The total profit in the six provinces accounted
for 62.42% of the total. Among the top 100, 26.7%
of the profit of Hong Kong, Macau, Taiwan and
foreign-funded companies came from Jiangsu, 9.11%
from Shanghai, 9.53% from Beijing, 11.24% from
Guangdong and 10.29% from Shandong.
13.45%
of the profit of joint stock companies came from
Jiangsu and 8% from Shandong, Zhejiang, Guangdong,
Beijing, Shanghai and Heilongjiang. Jiangsu
Province earned 37.59% of the total profit in the
chemical drugs and preparations sectors; Zhejiang
and Heilongjiang registered a growth of 23.75% and
19.33%, respectively, in the crude chemical drugs
sector; Shandong created the biggest profit in the
biomedicine sector, 35% of the total. The profit
for medical apparatus makers was concentrated in
Jiangsu, Guangdong and Beijing; and that for
Chinese patent medicines was concentrated in
Beijing, Guangdong, Jilin and Shandong.
In terms of sales revenue, Shanghai ranked
first with a growth of 13.36%, followed by
Shangdong (13.18%), Jiangsu (12.06%), Guangdong
(11.12%) and Zhejiang (10.12%). Jiangsu took up
the top 38.79% of the market shares in term of
chemical drugs and preparations. The income of
crude chemical drugs mainly came from Shandong, Hebei and Heilongjiang,
each accounting for 23.58%, 19.08% and 16.87%,
respectively.
Enterprises in Zhejiang
Province clinched 62.44% of the sales revenue in
the biomedicine sector, while that of Beijing,
Jiangsu, Liaoning and Shandong
were the main sources of the sales for medical
apparatus industry, and Chongqing, Jiangxi and Tianjin were the sources
of patent Chinese medicines.
